Biotech | August 18, 2021
ANG Lifesciences acquires Ind-Swift formulation facilities for Rs 60 cr
The company expects a potential sales turnover of Rs.350-500 crores at 100 % capacity utilization
The company expects a potential sales turnover of Rs.350-500 crores at 100 % capacity utilization
Brivaracetam tablets are indicated for the treatment of partial-onset seizures in patients four years of age and older
Domestic market and developing countries will need doses of Indian vaccines
The company reports revenue growth of 26% and PAT growth of 21% YoY
The group has a total of 320 ANDA approvals
The acquisition will provide it with a foothold in the US $ 48 billion global animal health market
It is indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus
Winlevi, the recently added anti-acne product with a new mechanism of action and broad-based use (vs Absorica), will further boost the derma portfolio and Speciality business growth
Domestic formulations business records 39 % growth while the international business revenue was largely flat as compared to Q1 FY21
The company has strong product launches both in India and overseas
Subscribe To Our Newsletter & Stay Updated
